Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient’s Pharmacy Network Program
FORT WASHINGTON, PA — Nabriva Therapeutics plc (NASDAQ: NBRV) announced that it has entered into an agreement with Vizient to offer XENLETA, which treats community-acquired bacterial pneumonia (CABP), as a …
Read More